Novo Nordisk to present array of new portfolio data including studies with semaglutide and CagriSema, expanding evidence in obesity and diabetes care at ADA 2025
Full data of Phase 3 REDEFINE 1 and 2 trial results will provide insights on the potential of CagriSema
Semaglutide real-world data complements evidence from previous cardiometabolic and kidney outcomes trials
Data on pipeline candidate amycretin to underscore Novo Nordisk's scientific efforts to continued innovation in obesity
PLAINSBORO, N.J., June 10, 2025 /PRNewswire/ -- Novo Nordisk today announced that new data from its industry-leading cardiometabolic portfolio will be showcased at the upcoming American Diabetes Association (ADA) 85th Scientific Sessions taking place in Chicago, June 20 – 23, 2025. A total of 29 abstracts will be presented, including trials investigating the efficacy and safety of CagriSema in people with overweight/obesity (REDEFINE 1) and those with overweight/obesity and type 2 diabetes (REDEFINE 2).1 Further, new data will complement the extensive body of cardiometabolic and kidney evidence for semaglutide in people with type 2 diabetes through analyses of the SOUL, STRIDE and FLOW trials, as well as insights from additional real-world studies in adults with obesity.2-4
"We recognize the complex interplay between cardiovascular and metabolic diseases, including type 2 diabetes and obesity, which require a personalized treatment approach," said Martin Holst Lange, Executive Vice President for Development at Novo Nordisk. "As we look to build an impactful portfolio of medicines to address patient needs, our data presented at ADA 2025 demonstrates not only how we are already delivering for a wide range of these needs with semaglutide, but that we are continuing to invest in innovation to support people living with serious chronic disease."
The presentation of the CagriSema REDEFINE 1 and 2 trials are the first ever Phase 3 data presented on a GLP-1 and amylin receptor agonist combination, offering insights into the potential of this investigational medicine. Data will also be presented on pipeline candidate amycretin, demonstrating Novo Nordisk's scientific efforts to deliver innovation in cardiometabolic diseases and individualized healthcare solutions.1
On June 22nd, Novo Nordisk will also host an R&D investor event on our metabolic and cardiovascular health portfolio to cover the science and abstracts presented at the congress. The event will be accessible via a live webcast on the Novo Nordisk investor website.
Full details of Novo Nordisk abstracts to be presented at ADA 2025. These data for medicines containing semaglutide, CagriSema, amycretin, insulin icodec, and IcoSema are investigational:
ADA Scientific Sessions:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
33 minutes ago
- Bloomberg
First China Weight Loss Drug Rival to Novo, Lilly Emerges
Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their first serious rival in China. Suzhou-based Innovent Biologics Inc. secured approval last week for its treatment mazdutide, a turning point in China's efforts to combat rising obesity and diabetes rates with local innovation. With over 600 million Chinese adults projected to be overweight by 2050, the emergence of a viable local alternative to Novo and Lilly's blockbuster GLP-1 treatments could make weight loss drugs more accessible in the world's second-largest economy.
Associated Press
7 hours ago
- Associated Press
Class Action Announcement HIMS: A Securities Fraud Class Action Lawsuit Was Filed Against Hims & Hers Health, Inc. (HIMS)
RADNOR, PA - June 29, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. ('Hims & Hers') ( NYSE: HIMS ) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is August 25, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Hims & Hers losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaints allege that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Hims & Hers was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk;' (2) as a result, there was a substantial risk that Hims & Hers' collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. THE LEAD PLAINTIFF PROCESS: Hims & Hers investors may, no later than August 25, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Hims & Hers investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. 280 King of Prussia Road Radnor, PA 19087 (484) 270-1453 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Yahoo
9 hours ago
- Yahoo
Medical Device Contract Manufacturing Market to Reach $171.19 Billion by 2032, Growing at a CAGR of 9.9% from 2025, Says Meticulous Research®
Market Growth Driven by Outsourcing Preferences, Advanced Manufacturing Technologies, Regulatory Compliance Expertise, and Industry 4.0 Integration REDDING, Calif., June 29, 2025 /PRNewswire/ -- According to a comprehensive market research report titled "Medical Device Contract Manufacturing Market Size, Share, Forecast, & Trends Analysis by Device (Biochemistry, Immunoassay, CT, MRI, X-ray, Ultrasound, Pacemaker, Defibrillator, Oximeter) Services (Development, Manufacturing, QA) – Global Forecast to 2032", the Medical Device Contract Manufacturing market is projected to reach $171.19 billion by 2032, up from an estimated $84.8 billion in 2025, growing at a robust CAGR of 9.9% during the forecast period. The growth of the medical device contract manufacturing market is driven by increasing preference for outsourcing design, development, and manufacturing in the MedTech sector amid rising regulatory complexity and cost optimization needs. The market's expansion is fueled by advanced manufacturing technologies, changing regulatory landscapes requiring specialized expertise, Industry 4.0 adoption, and growing healthcare expenditure across key global markets. The industry is experiencing revolutionary transformation through sophisticated automation integration, AI and robotics adoption, and development of specialized regulatory compliance solutions. Leading companies are embracing digital manufacturing technologies while expanding into emerging markets and developing innovative value-added services for medical device manufacturers worldwide. For more comprehensive insights, download the FREE report sample: Revolutionary Market Transformation Through Specialized Manufacturing Excellence The medical device contract manufacturing market represents a paradigm shift in healthcare technology production and regulatory compliance optimization. As medical device companies increasingly prioritize core competencies like research and development while seeking specialized manufacturing expertise, contract manufacturing offers a revolutionary solution that addresses the growing demand for cost-effective, regulatory-compliant, and technologically advanced medical device production. Market leaders are investing heavily in advanced automation technologies and regulatory expertise, establishing manufacturing capabilities that can deliver scalable, compliant medical device solutions. This technological advancement is making sophisticated medical device manufacturing increasingly accessible while delivering superior quality and regulatory compliance benefits. Dynamic Growth Across Key Market Segments Based on device type, the IVD Devices segment dominates the market in 2025, capturing approximately 21% of the total market share due to high burden of chronic and infectious diseases propelling R&D in IVD, high preference for outsourcing immunoassay analyzer development, and growing demand for automated ELISA platforms. However, the Drug Delivery Devices segment is experiencing the fastest growth with 11.2% CAGR, driven by rising chronic disease incidence, growing adoption of biologic drugs, and trend toward self-administration of medications. Based on risk classification, the Moderate-risk Medical Devices segment leads the market, reflecting feasible outsourcing opportunities with careful regulatory compliance, frequent utilization of devices like syringes and catheters, and growing adoption in home healthcare settings. This segment is also anticipated to record the highest growth rate during the forecast period. Based on services, the Design & Development segment accounts for approximately 24% of the market in 2025, attributed to growing demand for advanced medical devices, high costs associated with device development, and increasing trend toward outsourcing technical expertise. This segment is also expected to register the highest CAGR of 11.7% during the forecast period. Get Insightful Data on Regions, Market Segments, Customer Landscape, and Top Companies (Charts, Tables, Figures and More) - Strategic Market Opportunities and Innovation Drivers The market presents extraordinary growth opportunities through Industry 4.0 technology integration, emerging market expansion, and development of specialized regulatory compliance services. Companies are discovering new revenue streams through advanced automation capabilities and vertical supply chain integration while establishing comprehensive medical device manufacturing ecosystems. Key market drivers include: Outsourcing Preference Growth: Increasing trend toward outsourcing design, development, and manufacturing enabling medical device companies to focus on core competencies while reducing costs and time-to-market Advanced Manufacturing Technologies: Integration of AI, robotics, additive manufacturing, and IoT solutions enhancing efficiency, precision, and customization capabilities in medical device production Regulatory Landscape Evolution: Changing regulatory requirements compelling companies to seek specialized regulatory expertise and compliance services from experienced contract manufacturers Industry 4.0 Integration: Adoption of digital technologies, smart manufacturing systems, and blockchain-enabled traceability improving operational efficiency and regulatory compliance Regional Market Leadership and Emerging Growth North America commands the largest market share in 2025 with approximately 44% of the global market, driven by well-developed manufacturing infrastructure, presence of leading contract manufacturers, high adoption of advanced manufacturing technologies, and strong academia-industry collaboration fostering technological capabilities. Asia-Pacific emerges as the fastest-growing region with a projected CAGR of 11.9% during 2025-2032, propelled by availability of skilled labor at competitive costs, rising quality standards in manufacturing, government initiatives for local medical device production, and good accessibility to cheaper raw materials. Europe represents a significant market, supported by stringent regulatory frameworks, advanced manufacturing capabilities, growing demand for specialized medical devices, and presence of leading contract manufacturing providers with emphasis on quality and compliance. Request a customized research analysis tailored to your specific requirements: Dynamic Competitive Landscape Driving Innovation The global medical device contract manufacturing market features an innovative competitive ecosystem comprising specialized contract manufacturers, electronics manufacturing services providers, and integrated healthcare technology companies. This diverse landscape fosters rapid technological advancement through sophisticated automation integration and specialized regulatory expertise development. Industry leaders are implementing integrated solutions that combine advanced manufacturing technologies with comprehensive regulatory services and quality assurance capabilities. Companies are pursuing strategic mergers and acquisitions while addressing scalability and compliance challenges across different medical device segments. Immediate Delivery Available | Buy this Research Report (Insights, Charts, Tables, Figures and More) - Market Leaders Shaping Industry Future Key players driving the global medical device contract manufacturing market include Jabil Inc. (U.S.), Gerresheimer AG (Germany), Nordson Corporation (U.S.), Teleflex Incorporated (U.S.), Celestica Inc. (Canada), Plexus Corp (U.S.), SteriPack Group Ltd (U.S.), Nortech Systems, Inc. (U.S.), Invetech Pty. Ltd. (Australia), Flextronics International, LTD. (Singapore), Benchmark Electronics Inc. (U.S.), Integer Holdings Corporation (U.S.), and STRATEC SE (Germany). These companies are focusing on strategies such as advanced automation technology integration, specialized regulatory expertise development, comprehensive service portfolio expansion, strategic mergers and acquisitions, and geographic expansion into emerging markets to strengthen their market position. Latest Industry Developments Recent market developments include: Strategic CDMO Partnerships: Formation of Contract Development and Manufacturing Organization partnerships for specialized immunoassay systems and cartridge-based reagent manufacturing enhancing market capabilities Advanced Automation Integration: Implementation of AI and robotics technologies improving manufacturing efficiency, precision, and scalability while reducing time-to-market for medical devices Vertical Integration Initiatives: Strategic acquisitions enabling companies to optimize supply chains, enhance core capabilities, and diversify service offerings across the medical device value chain Market Challenges and Opportunities While the market shows strong growth potential, it faces challenges including complex regulatory compliance requirements across different jurisdictions, intellectual property protection concerns for high-risk devices, maintaining quality standards while reducing costs, and technical complexity in advanced medical device manufacturing. However, significant opportunities exist in expanding Industry 4.0 technology adoption, growing healthcare expenditure in developing countries, increasing demand for personalized medical devices, emerging applications in digital health and connected medical devices, and rising need for specialized manufacturing expertise in complex therapeutic areas. The Mid-scale Medical Device Companies segment is projected to experience rapid growth during the forecast period, driven by increasing focus on innovation and product introduction while adhering to cost constraints, competitive pressures requiring advanced manufacturing capabilities, and partnerships with contract manufacturers to offer high-quality products at competitive prices. Related Reports: Pharmaceutical Contract Development and Manufacturing Market Pharmaceutical Contract Packaging Market by Size, Share, Forecasts, & Trends Analysis IVD Contract Manufacturing Services Market by Size, Share, Forecasts IVD Assay Development Market Size, Share, Growth Analysis 2031 About Meticulous Research We are a trusted research partner for leading businesses worldwide, empowering Fortune 500 organizations and emerging enterprises with market intelligence designed to drive revenue transformation and strategic growth. Our insights reveal future growth opportunities, equipping clients with a competitive edge through a versatile suite of research solutions—including syndicated reports, custom research, and direct analyst engagement. To find out more, visit or follow us on LinkedIn Contact: Mr. Khushal Bombe Meticulous Market Research Pvt. Ltd. 1267 Willis St, Ste 200 Redding, California, 96001, U.S. USA: +1-646-781-8004 Europe: +44-203-868-8738 APAC: +91 744-7780008 Email- sales@ Visit Our Website: Connect with us on LinkedIn- Content Source: Logo - View original content to download multimedia: SOURCE Meticulous Market Research Private Limited Sign in to access your portfolio
